“Strike-outs” are inevitable as drug discovery is a complex endeavor and most trials end in failure, however, just a couple of “grand slams” should lead to outstanding overall performance in your portfolio over time.
A diversified portfolio with more heavily weighted large-cap growth names with long-term earnings visibility selling at reasonable valuations like Gilead Sciences (GILD) and Celgene (CELG), a couple winners that have returned profits within my diversified portfolio.
It is this well-thought-out investing strategy that even with an acceptable amount of volatility has led to exceptional overall performance. I have personally benefitted from this strong performance in the biotech sector. My analysis of these hot biotech stocks over the past few years has resulted in substantial growth and created profits in my own portfolio.
The Biotech Forum maintains a portfolio of 15 attractive small cap biotech stocks and five more heavily weighted large cap concerns creating a balanced portfolio geared to provide outstanding performance over time.
The Biotech Forum has delivered substantial outperformance compared to its benchmark and is highly ranked by our subscribers.